SUPPLEMENT

Q3 2021 — Financial disclosures

Q3 2021PDF · 10 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2021
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q21 and Sept YTD 21.......3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q20 and Sept YTD 20......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 3Q21........................................................6
Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 21............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	13,154	$ 	10,929	$ 	20% 	35,183	$ 	30,570	$ 	15%
Costs, Expenses and Other
Cost of sales 	3,450 	3,013 	15% 	9,752 	8,589 	14%
Selling, general and administrative 	2,336 	2,060 	13% 	6,804 	6,336 	7%
Research and development 	2,445 	3,349 	-27% 	9,177 	7,609 	21%
Restructuring costs (1) 107 	113 	-5% 	487 	265 	84%
Other (income) expense, net 	(450) 	(312) 	44% 	(1,007) 	(637) 	58%
Income from Continuing Operations Before Taxes 	5,266 	2,706 	95% 	9,970 	8,408 	19%
Income Tax Provision 	695 	380 	1,436 	1,271
Net Income from Continuing Operations 	4,571 	2,326 	97% 	8,534 	7,137 	20%
Less: Net Income Attributable to Noncontrolling Interests 	4 	2 	9 	1
Net Income from Continuing Operations Attributable to Merck & Co.,
Inc. 4,567	$ 	2,324	$ 	97% 	8,525	$ 	7,136	$ 	19%
Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests -	$ 	617	$ 	* 	766	$ 	2,025	$ 	-62%
Net Income Attributable to Merck & Co., Inc. 	4,567	$ 	2,941	$ 	55% 	9,291	$ 	9,161	$ 	1%
Basic Earnings per Common Share Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	1.81	$ 	0.92	$ 	97% 	3.37	$ 	2.82	$ 	20%
Income from Discontinued Operations 	-	$ 	0.24	$ 	* 	0.30	$ 	0.80	$ 	-63%
Net Income 	1.81	$ 	1.16	$ 	56% 	3.67	$ 	3.62	$ 	1%
Earnings per Common Share Assuming Dilution Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.80	$ 	0.92	$ 	96% 	3.36	$ 	2.81	$ 	20%
Income from Discontinued Operations 	-	$ 	0.24	$ 	* 	0.30	$ 	0.80	$ 	-63%
Net Income 	1.80	$ 	1.16	$ 	55% 	3.66	$ 	3.61	$ 	1%
Average Shares Outstanding 	2,530 	2,529 	2,531 	2,530
Average Shares Outstanding Assuming Dilution 	2,536 	2,538 	2,539 	2,541
Tax Rate from Continuing Operations (2) 13.2% 	14.0% 	14.4% 	15.1%
* 100% or greater
(2) The effective income tax rate for the first nine months of 2021 reflects the unfavorable impact of a charge for the acquisition of Pandion Therapeutics, Inc. for which no tax benefit
was recognized and a net tax benefit of $207 million related to the settlement of certain federal income tax matters.
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
3Q21
On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company
shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off
are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided
below.
3Q20 Sep YTD
2021
Sep YTD
2020
(1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.
1

-- 2 of 10 --

Sales 	10,627	$ 	11,402	$ 	13,154	$ 	35,183	$ 	10,288	$ 	9,353	$ 	10,929	$ 	30,570	$ 	10,948	$ 	41,518	$ 	20% 	15%
Costs, Expenses and Other
Cost of sales 	3,199 	3,104 	3,450 	9,752 	2,829 	2,747 	3,013 	8,589 	5,029 	13,618 	15% 	14%
Selling, general and administrative 	2,187 	2,281 	2,336 	6,804 	2,191 	2,085 	2,060 	6,336 	2,619 	8,955 	13% 	7%
Research and development 	2,412 	4,321 	2,445 	9,177 	2,175 	2,085 	3,349 	7,609 	5,788 	13,397 	-27% 	21%
Restructuring costs 	297 	82 	107 	487 	70 	82 	113 	265 	310 	575 	-5% 	84%
Other (income) expense, net 	(455) 	(103) 	(450) 	(1,007) 	62 	(387) 	(312) 	(637) 	(253) 	(890) 	44% 	58%
Income (Loss) from Continuing Operations Before Taxes 	2,987 	1,717 	5,266 	9,970 	2,961 	2,741 	2,706 	8,408 	(2,545) 	5,863 	95% 	19%
Income Tax Provision 	238 	503 	695 	1,436 	495 	396 	380 	1,271 	69 	1,340
Net Income (Loss) from Continuing Operations 	2,749 	1,214 	4,571 	8,534 	2,466 	2,345 	2,326 	7,137 	(2,614) 	4,523 	97% 	20%
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	1 	4 	9 	(5) 	4 	2 	1 	3 	4
Net Income (Loss) from Continuing Operations Attributable to
Merck & Co., Inc.
2,745 	1,213 	4,567 	8,525 	2,471 	2,341 	2,324 	7,136 	(2,617) 	4,519 	97% 	19%
Income from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
434 	332 	- 	766 	748 	661 	617 	2,025 	523 	2,548 	* 	-62%
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,179	$ 	1,545	$ 	4,567	$ 	9,291	$ 	3,219	$ 	3,002	$ 	2,941	$ 	9,161	$ 	(2,094)	$ 	7,067	$ 	55% 	1%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.81	$ 	3.37	$ 	0.98	$ 	0.93	$ 	0.92	$ 	2.82	$ 	(1.03)	$ 	1.79	$ 	97% 	20%
Income from Discontinued Operations 	0.17 	0.13 	- 	0.30 	0.30 	0.26 	0.24 	0.80 	0.21 	1.01 	* 	-63%
Net Income (Loss) 	1.26	$ 	0.61	$ 	1.81	$ 	3.67	$ 	1.27	$ 	1.19	$ 	1.16	$ 	3.62	$ 	(0.83)	$ 	2.79	$ 	56% 	1%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations 	1.08	$ 	0.48	$ 	1.80	$ 	3.36	$ 	0.97	$ 	0.92	$ 	0.92	$ 	2.81	$ 	(1.03)	$ 	1.78	$ 	96% 	20%
Income from Discontinued Operations 	0.17 	0.13 	- 	0.30 	0.29 	0.26 	0.24 	0.80 	0.21 	1.00 	* 	-63%
Net Income (Loss) 	1.25	$ 	0.61	$ 	1.80	$ 	3.66	$ 	1.26	$ 	1.18	$ 	1.16	$ 	3.61	$ 	(0.83)	$ 	2.78	$ 	55% 	1%
Average Shares Outstanding 	2,531 	2,533 	2,530 	2,531 	2,533 	2,527 	2,529 	2,530 	2,530 	2,530
Average Shares Outstanding Assuming Dilution (1) 	2,541 	2,540 	2,536 	2,539 	2,547 	2,536 	2,538 	2,541 	2,530 	2,541
Tax Rate from Continuing Operations 	8.0% 	29.3% 	13.2% 	14.4% 	16.7% 	14.4% 	14.0% 	15.1% 	-2.7% 	22.9%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
3Q 	Sep YTD
(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding.
2021
2Q 	3Q 	Sep YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2020
Sep YTD
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 10 --

Third Quarter
Cost of sales 	3,450	$ 	346 	48 	394 	3,056	$
Selling, general and administrative 	2,336 	61 	5 	66 	2,270
Research and development 	2,445 	48 	8 	(87) (4) (31) 	2,476
Restructuring costs 	107 	107 	107 	-
Other (income) expense, net 	(450) 	(10) 	(684) 	(694) 	244
Income From Continuing Operations Before Taxes 	5,266 	(445) 	(168) 	684 	87 	158 	5,108
Income Tax Provision (Benefit) 	695 	(96) (5) (26) (5) 151 (5) 1 (5) 30 	665
Net Income from Continuing Operations 	4,571 	(349) 	(142) 	533 	86 	128 	4,443
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 4,567 	(349) 	(142) 	533 	86 	128 	4,439
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.80	$ 	(0.14) 	(0.06) 	0.21 	0.04 	0.05 	1.75	$
Tax Rate 	13.2% 	13.0%
Sep YTD
Cost of sales 	9,752	$ 	1,188 	113 	225 (3) 1,526 	8,226	$
Selling, general and administrative 	6,804 	96 	9 	105 	6,699
Research and development 	9,177 	82 	21 	1,678 (4) 1,781 	7,396
Restructuring costs 	487 	487 	487 	-
Other (income) expense, net 	(1,007) 	79 	(1,503) 	(1,424) 	417
Income From Continuing Operations Before Taxes 	9,970 	(1,445) 	(630) 	1,503 	(1,903) 	(2,475) 	12,445
Income Tax Provision (Benefit) 	1,436 	(283) (5) (82) (5) 331 (5) (259) (5) (293) 	1,729
Net Income from Continuing Operations 	8,534 	(1,162) 	(548) 	1,172 	(1,644) 	(2,182) 	10,716
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 8,525 	(1,162) 	(548) 	1,172 	(1,644) 	(2,182) 	10,707
Earnings per Common Share Assuming Dilution from
Continuing Operations 3.36	$ 	(0.46) 	(0.22) 	0.46 	(0.65) 	(0.86) 	4.22	$
Tax Rate 	14.4% 	13.9%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs.
Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine months period
primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture. Additionally, the first nine months also
includes a loss on a forward exchange contract entered into in conjunction with the Organon spinoff. Amount included in other (income) expense, net, for the nine month period is partially offset by royalty income related to
the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents charges for the discontinuation of COVID-19 development programs.
(5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a
$207 million net tax benefit related to the settlement of certain federal income tax matters.
(4) Amounts included in the third quarter and first nine months reflect a $90 million adjustment to deferred tax assets identified in conjunction with the VelosBio Inc. acquisition. Additionally, the first nine months includes a
$1.7 billion charge for the acquisition of Pandion Therapeutics, Inc.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
Table 2a
3

-- 4 of 10 --

Third Quarter
Cost of sales 	3,013	$ 	403 	38 	441 	2,572	$
Selling, general and administrative 	2,060 	25 	15 	40 	2,020
Research and development 	3,349 	19 	19 	1,082 (3) 1,120 	2,229
Restructuring costs 	113 	113 	113 	-
Other (income) expense, net 	(312) 	(346) 	(1) 	(347) 	35
Income From Continuing Operations Before Taxes 	2,706 	(447) 	(185) 	346 	(1,081) 	(1,367) 	4,073
Income Tax Provision (Benefit) 	380 	(9) (4) (25) (4) 76 (4) (247) (4) (205) 	585
Net Income from Continuing Operations 	2,326 	(438) 	(160) 	270 	(834) 	(1,162) 	3,488
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 2,324 	(438) 	(160) 	270 	(834) 	(1,162) 	3,486
Earnings per Common Share Assuming Dilution from
Continuing Operations 0.92	$ 	(0.17) 	(0.06) 	0.11 	(0.33) 	(0.45) 	1.37	$
Tax Rate 	14.0% 	14.4%
Sep YTD
Cost of sales 	8,589	$ 	1,370 	131 	1,501 	7,088	$
Selling, general and administrative 	6,336 	182 	37 	219 	6,117
Research and development 	7,609 	(4) 	67 	1,082 (3) 1,145 	6,464
Restructuring costs 	265 	265 	265 	-
Other (income) expense, net 	(637) 	52 	(944) 	(17) 	(909) 	272
Income From Continuing Operations Before Taxes 	8,408 	(1,600) 	(500) 	944 	(1,065) 	(2,221) 	10,629
Income Tax Provision (Benefit) 	1,271 	(251) (4) (59) (4) 208 (4) (242) (4) (344) 	1,615
Net Income from Continuing Operations 	7,137 	(1,349) 	(441) 	736 	(823) 	(1,877) 	9,014
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 7,136 	(1,349) 	(441) 	736 	(823) 	(1,877) 	9,013
Earnings per Common Share Assuming Dilution from
Continuing Operations 2.81	$ 	(0.54) 	(0.17) 	0.29 	(0.32) 	(0.74) 	3.55	$
Tax Rate 	15.1% 	15.2%
Only the line items that are affected by non-GAAP adjustments are shown.
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
MERCK & CO., INC.
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax
income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related
costs, including $95 million of transaction costs in the nine month period related to the acquisition of Arqule, Inc. Amounts included in research and development expenses primarily reflect a reduction in expenses related to
a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value
measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost
of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment Subtotal
(3) Represents expenses for upfront payments related to license and collaboration agreements.
4

-- 5 of 10 --

1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $10,627 	$11,402 	$13,154 	$35,183 	$10,288 	$9,353 	$10,929 	$30,570 	$10,948 	$41,518 	20 	19 	15 	13
PHARMACEUTICAL 	9,238 	9,980 	11,496 	30,714 	8,905 	8,178 	9,714 	26,797 	9,813 	36,610 	18 	17 	15 	12
Oncology
Keytruda 	3,899 	4,176 	4,534 	12,609 	3,284 	3,388 	3,715 	10,387 	3,993 	14,380 	22 	21 	21 	19
Alliance Revenue – Lynparza (2) 228 	248 	246 	721 	145 	178 	196 	519 	206 	725 	25 	25 	39 	35
Alliance Revenue – Lenvima (2) 130 	181 	188 	498 	128 	151 	142 	421 	158 	580 	32 	30 	18 	15
Vaccines (3)
Gardasil / Gardasil 9 	917 	1,234 	1,993 	4,144 	1,097 	656 	1,187 	2,941 	998 	3,938 	68 	63 	41 	35
ProQuad / M-M-R II / Varivax 	449 	516 	661 	1,626 	435 	378 	576 	1,390 	488 	1,878 	15 	14 	17 	16
Pneumovax 23 	171 	152 	277 	600 	256 	117 	375 	748 	339 	1,087 	-26 	-26 	-20 	-21
RotaTeq 	158 	208 	227 	593 	222 	168 	210 	601 	196 	797 	8 	7 	-1 	-3
Vaqta 	34 	56 	48 	138 	60 	28 	51 	139 	31 	170 	-6 	-6 	-1 	-2
Hospital Acute Care
Bridion 	340 	387 	369 	1,096 	299 	224 	320 	843 	355 	1,198 	16 	15 	30 	27
Prevymis 	82 	93 	96 	270 	60 	63 	77 	200 	80 	281 	23 	22 	35 	31
Noxafil 	67 	66 	64 	197 	94 	73 	79 	247 	82 	329 	-19 	-20 	-20 	-23
Primaxin 	65 	60 	70 	194 	51 	64 	74 	189 	62 	251 	-6 	-12 	3 	-4
Cancidas 	57 	54 	56 	168 	55 	43 	50 	148 	65 	213 	13 	9 	13 	8
Invanz 	57 	48 	53 	157 	64 	43 	51 	159 	53 	211 	5 	0 	-1 	-4
Zerbaxa 	(8) 	(1) 	(2) 	(11) 	37 	32 	43 	112 	19 	130 	-105 	-105 	-110 	-110
Immunology
Simponi 	214 	202 	203 	619 	215 	191 	209 	615 	223 	838 	-3 	-5 	1 	-5
Remicade 	85 	75 	73 	233 	88 	73 	82 	242 	88 	330 	-11 	-11 	-4 	-8
Neuroscience
Belsomra 	79 	78 	81 	238 	79 	84 	81 	244 	83 	327 	0 	3 	-2 	-2
Virology
Isentress / Isentress HD 	209 	192 	189 	590 	245 	196 	205 	646 	211 	857 	-8 	-7 	-9 	-9
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 74 	74 	100 	248 	53 	79 	83 	216 	65 	281 	20 	20 	15 	15
Adempas (5) 55 	74 	59 	188 	56 	57 	55 	167 	53 	220 	7 	8 	13 	7
Diabetes (6)
Januvia 	809 	784 	852 	2,445 	774 	854 	821 	2,449 	857 	3,306 	4 	3 	0 	-3
Janumet 	486 	477 	487 	1,449 	503 	490 	506 	1,499 	472 	1,971 	-4 	-6 	-3 	-7
Other Pharmaceutical (7) 581 	546 	572 	1,704 	605 	548 	526 	1,675 	636 	2,312 	9 	8 	2 	1
ANIMAL HEALTH 	1,418 	1,472 	1,417 	4,307 	1,214 	1,101 	1,220 	3,535 	1,168 	4,703 	16 	14 	22 	19
Livestock 	819 	821 	864 	2,503 	739 	648 	758 	2,145 	794 	2,939 	14 	12 	17 	14
Companion Animals 	599 	651 	553 	1,804 	475 	453 	462 	1,390 	374 	1,764 	20 	18 	30 	26
Other Revenues (8) (29) 	(50) 	241 	162 	169 	74 	(5) 	238 	(33) 	205 	* 	* 	-32 	88
* 200% or greater
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,363 million, $1,330 million, and $1,417 million in the first, second, and third quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million
in the first, second, third and fourth quarters of 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the third quarter and
September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $1,809 million, $2,293 million, and $3,315 million in the first, second, and third quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million
in the first, second, third and fourth quarters of 2020, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2021 	2020 	3Q 	September YTD
5

-- 6 of 10 --

3Q 2021 	3Q 2020 	% Change 	3Q 2021 	3Q 2020 	% Change 	3Q 2021 	3Q 2020 	% Change
TOTAL SALES (1) $13,154 	$10,929 	20 	$6,276 	$5,250 	20 	$6,878 	$5,679 	21
PHARMACEUTICAL 	11,496 	9,714 	18 	5,670 	4,842 	17 	5,826 	4,872 	20
Oncology
Keytruda 	4,534 	3,715 	22 	2,580 	2,157 	20 	1,954 	1,559 	25
Alliance Revenue - Lynparza (2) 246 	196 	25 	129 	107 	21 	117 	89 	31
Alliance Revenue - Lenvima (2) 188 	142 	32 	114 	82 	40 	74 	60 	23
Vaccines (3)
Gardasil / Gardasil 9 	1,993 	1,187 	68 	839 	579 	45 	1,154 	608 	90
ProQuad / M-M-R II / Varivax 	661 	576 	15 	537 	437 	23 	125 	139 	-10
Pneumovax 23 	277 	375 	-26 	181 	276 	-34 	97 	99 	-3
RotaTeq 	227 	210 	8 	135 	114 	19 	92 	96 	-4
Vaqta 	48 	51 	-6 	32 	32 	2 	16 	19 	-19
Hospital Acute Care
Bridion 	369 	320 	16 	181 	162 	11 	188 	157 	20
Prevymis 	96 	77 	23 	39 	32 	22 	57 	46 	24
Noxafil 	64 	79 	-19 	19 	13 	44 	45 	66 	-31
Primaxin 	70 	74 	-6 	1 	-64 	69 	73 	-5
Cancidas 	56 	50 	13 	1 	1 	-19 	56 	49 	14
Invanz 	53 	51 	5 	(2) 	1 	* 	55 	50 	12
Zerbaxa 	(2) 	43 	-105 	(1) 	20 	-106 	(1) 	23 	-104
Immunology
Simponi 	203 	209 	-3 	203 	209 	-3
Remicade 	73 	82 	-11 	73 	82 	-11
Neuroscience
Belsomra 	81 	81 	23 	18 	32 	58 	63 	-8
Virology
Isentress / Isentress HD 	189 	205 	-8 	77 	92 	-16 	112 	113 	-1
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 100 	83 	20 	73 	78 	-7 	27 	5 	*
Adempas (5) 59 	55 	7 	0 	- 	59 	55 	7
Diabetes (6)
Januvia 	852 	821 	4 	365 	342 	7 	487 	479 	2
Janumet 	487 	506 	-4 	86 	105 	-18 	401 	400
Other Pharmaceutical (7) 572 	526 	9 	262 	193 	36 	308 	333 	-8
ANIMAL HEALTH 	1,417 	1,220 	16 	467 	399 	17 	951 	821 	16
Livestock 	864 	758 	14 	190 	165 	15 	675 	593 	14
Companion Animals 	553 	462 	20 	277 	234 	18 	276 	228 	21
Other Revenues (8) 241 	(5) 	* 	139 	9 	* 	101 	(14) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the
third quarter of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $3,315 million in the third quarter of 2021 and $2,521 million in the third quarter of 2020.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $1,417 million in the third quarter of 2021 and $1,405 million in the third quarter of 2020.
(7) Includes Pharmaceutical products not individually shown above.
(1) Only select products are shown.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
THIRD QUARTER 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
6

-- 7 of 10 --

September
YTD 2021
September
YTD 2020 	% Change
September
YTD 2021
September
YTD 2020 	% Change
September
YTD 2021
September
YTD 2020 	% Change
TOTAL SALES (1) $35,183 	$30,570 	15 	$16,166 	$14,301 	13 	$19,017 	$16,269 	17
PHARMACEUTICAL 	30,714 	26,797 	15 	14,611 	13,108 	11 	16,103 	13,690 	18
Oncology
Keytruda 	12,609 	10,387 	21 	7,108 	6,106 	16 	5,501 	4,281 	29
Alliance Revenue - Lynparza (2) 721 	519 	39 	371 	297 	25 	350 	223 	57
Alliance Revenue - Lenvima (2) 498 	421 	18 	287 	270 	6 	211 	152 	39
Vaccines (3)
Gardasil / Gardasil 9 	4,144 	2,941 	41 	1,605 	1,209 	33 	2,539 	1,732 	47
ProQuad / M-M-R II / Varivax 	1,626 	1,390 	17 	1,255 	1,033 	21 	371 	356 	4
Pneumovax 23 	600 	748 	-20 	354 	478 	-26 	247 	270 	-9
RotaTeq 	593 	601 	-1 	364 	355 	3 	229 	246 	-7
Vaqta 	138 	139 	-1 	80 	79 	1 	58 	60 	-4
Hospital Acute Care
Bridion 	1,096 	843 	30 	545 	412 	32 	551 	431 	28
Prevymis 	270 	200 	35 	111 	87 	28 	159 	113 	40
Noxafil 	197 	247 	-20 	48 	27 	79 	149 	220 	-32
Primaxin 	194 	189 	3 	2 	-79 	194 	187 	4
Cancidas 	168 	148 	13 	4 	2 	129 	164 	147 	12
Invanz 	157 	159 	-1 	(2) 	7 	-128 	159 	152 	5
Zerbaxa 	(11) 	112 	-110 	(5) 	57 	-109 	(6) 	54 	-111
Immunology
Simponi 	619 	615 	1 	619 	615 	1
Remicade 	233 	242 	-4 	233 	242 	-4
Neuroscience
Belsomra 	238 	244 	-2 	56 	67 	-17 	183 	177 	3
Virology
Isentress / Isentress HD 	590 	646 	-9 	222 	243 	-9 	368 	403 	-9
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 248 	216 	15 	222 	200 	11 	26 	16 	67
Adempas (5) 188 	167 	13 	0 	- 	188 	167 	13
Diabetes (6)
Januvia 	2,445 	2,449 	997 	1,110 	-10 	1,448 	1,339 	8
Janumet 	1,449 	1,499 	-3 	244 	361 	-32 	1,205 	1,138 	6
Other Pharmaceutical (7) 1,704 	1,675 	2 	745 	706 	6 	957 	969 	-1
ANIMAL HEALTH 	4,307 	3,535 	22 	1,363 	1,124 	21 	2,944 	2,411 	22
Livestock 	2,503 	2,145 	17 	508 	448 	13 	1,996 	1,697 	18
Companion Animals 	1,804 	1,390 	30 	855 	676 	26 	948 	714 	33
Other Revenues (8) 162 	238 	-32 	192 	69 	181 	(30) 	168 	-118
Sum of U.S. plus international may not equal global due to rounding.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(5) Net product sales in Merck's marketing territories.
(6) Total Diabetes sales were $4,110 million and $4,177 million on a global basis for September YTD 2021 and 2020, respectively.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the
September year-to-date period of 2021 include $135 million related to the receipt of a milestone payment for an out-licensed product.
(3) Total Vaccines sales were $7,417 million and $6,094 million on a global basis for September YTD 2021 and 2020, respectively.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
SEPTEMBER YEAR-TO-DATE 2021
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
7

-- 8 of 10 --

TOTAL PHARMACEUTICAL 	$9,238 	$9,980 	$11,496 	$30,714 	$8,905 	$8,178 	$9,714 	$26,797 	$9,813 	$36,610 	18 	15
United States 	4,294 	4,647 	5,670 	14,611 	4,308 	3,958 	4,842 	13,108 	4,903 	18,010 	17 	11
% Pharmaceutical Sales 	46.5% 	46.6% 	49.3% 	47.6% 	48.4% 	48.4% 	49.8% 	48.9% 	50.0% 	49.2%
Europe (1) 2,276 	2,404 	2,445 	7,124 	2,116 	1,855 	2,171 	6,141 	2,314 	8,455 	13 	16
% Pharmaceutical Sales 	24.6% 	24.1% 	21.3% 	23.2% 	23.8% 	22.7% 	22.3% 	22.9% 	23.6% 	23.1%
China 	688 	944 	1,278 	2,910 	628 	600 	764 	1,992 	670 	2,661 	67 	46
% Pharmaceutical Sales 	7.4% 	9.5% 	11.1% 	9.5% 	7.1% 	7.3% 	7.9% 	7.4% 	6.8% 	7.3%
Japan 	607 	637 	614 	1,858 	561 	601 	648 	1,810 	704 	2,514 	-5 	3
% Pharmaceutical Sales 	6.6% 	6.4% 	5.3% 	6.0% 	6.3% 	7.3% 	6.7% 	6.8% 	7.2% 	6.9%
Asia Pacific (other than China and Japan) 	437 	442 	450 	1,329 	411 	377 	411 	1,200 	414 	1,614 	9 	11
% Pharmaceutical Sales 	4.7% 	4.4% 	3.9% 	4.3% 	4.6% 	4.6% 	4.2% 	4.5% 	4.2% 	4.4%
Latin America 	353 	379 	434 	1,166 	314 	312 	372 	998 	371 	1,369 	17 	17
% Pharmaceutical Sales 	3.8% 	3.8% 	3.8% 	3.8% 	3.5% 	3.8% 	3.8% 	3.7% 	3.8% 	3.7%
Eastern Europe/Middle East/Africa 	357 	318 	362 	1,037 	353 	309 	289 	948 	251 	1,199 	25 	9
% Pharmaceutical Sales 	3.9% 	3.2% 	3.1% 	3.4% 	4.0% 	3.8% 	3.0% 	3.5% 	2.6% 	3.3%
Canada 	160 	157 	164 	482 	159 	121 	169 	449 	149 	599 	-3 	7
% Pharmaceutical Sales 	1.7% 	1.6% 	1.4% 	1.6% 	1.8% 	1.5% 	1.7% 	1.7% 	1.5% 	1.6%
Other 	66 	52 	79 	197 	55 	45 	48 	151 	37 	189 	65 	30
% Pharmaceutical Sales 	0.8% 	0.4% 	0.8% 	0.6% 	0.5% 	0.6% 	0.6% 	0.6% 	0.3% 	0.5%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
3Q 	Sep YTD 	4Q 	Full Year 	3Q 	Sep YTD	1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q
2021 	2020 	% Change
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
3Q21 	3Q20
Sep YTD
2021
Sep YTD
2020
Interest income 	(7)	$ 	(9)	$ 	(27)	$ 	(48)	$
Interest expense 	196 	203 	597 	624
Exchange losses 	46 	10 	202 	89
Income from investments in equity securities, net (1) (683) 	(360) 	(1,535) 	(964)
Net periodic defined benefit plan cost (credit) other than service cost 	40 	(88) 	(159) 	(259)
Other, net 	(42) 	(68) 	(85) 	(79)
Total 	(450)	$ 	(312)	$ 	(1,007)	$ 	(637)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds
are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --